US4705789A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Solutions of lactic acid salts of piperazinylquinolone- and piperazinyl-azaquinolone-carboxylic acids
Assignee: Bayer AG
•
Filing: 1984-08-27
•
Granted: 1987-11-10
•
Expires: 2004-08-27
Abstract
Abstract The invention relates to solutions of piperazinyl-quinolone- and piperazinyl-azaquinolone-carboxylic acids, and in particular both ready-to-use injection and/or infusion solutions and dosage forms which can be converted into such injection and/or infusion solutions before use. The solutions according to the invention are characterized in that, besides the lactic acid salts of the active substance and, if appropriate, customary auxiliaries, they additionally contain at least one acid which does not lead to precipitates, in particular lactic acid.
Inventors
- 👤 Klaus Grohe
- 👤 Robert Lammens
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 09:46
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04; A; A61; A61K; A61K47/00; A61K47/06; A61K47/08; A61K47/12; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/535; A61K9/00; A61K9/0012; A61K9/0019; A61K9/08; A61P; A61P31/00; A61P31/04
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
101 words
An aqueous storage stable solution which can be converted into injection or diffusion solution, comprising a solution of (a) a lactic acid salt of at least one of a piperazinylquinolone- and a piperazinyl containing azaquinoline-carboxylic acid of the formula I and II ##STR2## in which X denotes N, C--H or C--F, Z denotes CH 2 , R 1 denotes hydrogen, methyl, ethyl or β-hydroxyethyl, R 2 denotes cyclopropyl or ethyl and R 3 denotes hydrogen, methyl or ethyl, and (b) excess lactic acid, the excess lactic acid being present in from 0.01 to 90% of the amount based on the solution.
Claim 2
Dependent Claim
101 words
An aqueous storage stable solution which can be converted into injection or diffusion solution, comprising a solution of (a) a lactic acid salt of at least one of a piperazinylquinolone- and a piperazinyl containing azaquinoline-carboxylic acid of the formula I and II ##STR2## in which X denotes N, C--H or C--F, Z denotes CH 2 , R 1 denotes hydrogen, methyl, ethyl or β-hydroxyethyl, R 2 denotes cyclopropyl or ethyl and R 3 denotes hydrogen, methyl or ethyl, and (b) excess lactic acid, the excess lactic acid being present in from 0.01 to 90% of the amount based on the solution.
Claim 3
Dependent Claim
12 words
A solution according to claim 1 additionally containing a non-toxic pharmaceutical carrier.
Claim 4
Dependent Claim
18 words
A solution according to claim 1, which contains the lactate of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylic acid as the lactic acid salt.
Claim 5
Dependent Claim
13 words
A solution according to claim 1, which contains the lactate of 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylic acid.
Claim 6
Dependent Claim
13 words
A solution according to claim 1, which contains the lactate of 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl-1,8-naphthyridine-3-carboxylic acid.
Claim 7
Dependent Claim
17 words
A solution according to claim 1, which the content of excess lactic acid is 0.01 to 2.5%.
Claim 8
Dependent Claim
18 words
A solution according to claim 1, in which the content of excess lactic acid is 0.01 to 1.4%.
References Cited (Backward Citations)
DE296839C
Cited
US4022894A
Cited
EP0009425A1
Cited
DE2918319A1
Cited
DE3037103A1
Cited
EP0047005B1
Cited
EP0067666A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-11-09 | 1991-05-11 | 1991-11-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-11-09 | 1995-05-11 | 1995-11-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-11-09 | 1999-05-11 | 1999-11-10 | $7700.00 | Window Closed / Lapsed |